February 4th is World Cancer Day, dedicated to informing and raising general public awareness of the various forms of a disease that continues to claim lives.
This year marks the 20th anniversary of the World Cancer Day. Initiated by six international experts in 2000, this day is based on a charter that highlights the need for access to quality care, funding for cancer research, greater understanding and above all respect and dignity for all individuals living with the disease.
According to the World Health Organization, there will be 233 million new cases of cancer by the year 2030. To fulfill the growing needs of patients, Servier has made oncology one of its priority research areas – as reflected by the partnership with Taiho Pharmaceutical in the co-development of a digestive oncology drug in 2015, the acquisition of Shire’s oncology branch in 2018 and the launch by Servier’s US subsidiary of a product in onco-hematology in the United States, the world’s leading pharmaceutical market, in 2019.
In 2021, the Group intends to devote 50% of its overall R&D budget to research into cancer treatments, compared to 36% at the end of 2019.
Servier’s R&D programs focus on two paths: therapies to restore programmed cell death (apoptosis) and therapies aimed at stimulating the patient’s own immune system against cancer cells, immuno-oncology.
Innovation in oncology also relies on close collaboration between the players involved in the research and development of new cancer treatments. Servier has entered into numerous partnerships with academic institutions and biotechs in order to go further, faster.
Interview of Patrick Therasse, Head R&D Oncology
Create a future without cancer. The time to act is now (Worldcancerday.org)
Up to 3.7 million lives could be saved each year by implementing appropriate resources and strategies for prevention, early detection and treatment of cancer.
Mark World Cancer Day in your own way. To find out more.